Tafinlar (dabrafenib)
Active ingredients · Dabrafenib Mesylate
75 mg/1 · Capsule
By Novartis Pharmaceuticals Corporation
- NDC
- 0078-0681
- Route
- Oral
- Therapeutic class
- Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C8 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A4 Inducers [MoA], Kinase Inhibitor , Organic Anion Transporter 1 Inhibitors [MoA], Organic Anion Transporter 3 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], Protein Kinase Inhibitors [MoA]
- Marketing category
- NDA
Package sizes
- 120 CAPSULE in 1 BOTTLE (0078-0681-66)NDC 0078-0681-66Available to order
Additional information
Full prescribing information for this product is available on request. Submit a sourcing request and our team will share lot details, dating, and current pricing.
Request this medication
Send a request and we'll respond with availability, lot details, and pricing within 2 business hours.
Related in Oncology & Specialty
See all →Verzenio (abemaciclib)
50 mg/1 · Tablet
Eli Lilly and Company
Available to source
Verzenio (abemaciclib)
200 mg/1 · Tablet
Eli Lilly and Company
Available to source
Verzenio (abemaciclib)
100 mg/1 · Tablet
Eli Lilly and Company
Available to source
Verzenio (abemaciclib)
150 mg/1 · Tablet
Eli Lilly and Company
Available to source
